Virus Transmission to People Recently Bitten or With a History of Monkey Bites "SIMVIR

NCT ID: NCT07097480

Last Updated: 2025-07-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-07-31

Study Completion Date

2028-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Nonhuman primates (NHPs) constitute an important reservoir of infectious agents, some of which have emerged in human populations as deadly pathogens. Human exposure to the biological fluids of NHPs - particularly through bites - can result in the transmission of several viruses. Only the rabies virus is currently targeted by post-exposure prophylaxis following an injury caused by an NHP.

The objective of the study is to investigate the prevalence of STLV-1 and SFV infections following a nonhuman primate bite.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Nonhuman primates (NHPs) constitute an important reservoir of infectious agents, some of which have emerged in human populations as deadly pathogens. Human exposure to the biological fluids of NHPs - particularly through bites - can result in the transmission of several viruses. Only the rabies virus is currently targeted by post-exposure prophylaxis following an injury caused by an NHP.

Compared to other individuals exposed to nonhuman primates (NHPs), travelers have two unique characteristics. First, they are typically exposed only once to simian infectious agents, in contrast to the repeated exposure experienced by other at-risk groups. If exposure results in an infection event, travelers may spread these infectious agents to geographic areas where they do not normally circulate.

To address the following main objective: to study the prevalence of STLV-1 and SFV infections following a nonhuman primate bite. The study plans to include subjects who have been recently bitten as well as those with a history of nonhuman primate bites. Blood and saliva samples will be collected from the subjects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bites Monkey

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Antirabies Virus Bite Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Adults recently bitten by a non-human primate

Adults recently bitten by a non-human primate and consulting at the Institut Pasteur medical center for prophylaxis as part of their care.

Group Type OTHER

Blood samples collection

Intervention Type PROCEDURE

Blood samples of 40 ml will be taken.

Saliva samples collection

Intervention Type PROCEDURE

Saliva samples will be collected

Adults with a history of bites

Adults with a history of bites from a non-human primate who are consulting at the Institut Pasteur medical center as part of their routine care.

Group Type OTHER

Blood samples collection

Intervention Type PROCEDURE

Blood samples of 40 ml will be taken.

Saliva samples collection

Intervention Type PROCEDURE

Saliva samples will be collected

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood samples collection

Blood samples of 40 ml will be taken.

Intervention Type PROCEDURE

Saliva samples collection

Saliva samples will be collected

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* Bite inflicted by an HNP (WHO category 3 level)
* Written informed consent
* Affiliation with a social security scheme (excluding State Medical Aid

Specific criteria for genetic analyses:

* Participant has checked the boxes for participation in the genetic component.

Exclusion Criteria

* Patient presenting only with scratches inflicted by a PNH
* Medical management incompatible with the objectives of the study
* Patient who, in the doctor's opinion, is unlikely to comply with the study protocol
* Health conditions are incompatible with the sample collection required by the study
* Patient under legal protection (guardianship or trusteeship)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institut Pasteur

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Patrick HOCHEDEZ, Dr

Role: PRINCIPAL_INVESTIGATOR

Institut Pasteur Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institut Pasteur Medical Center

Paris, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Florence BUSEYNE, PhD

Role: CONTACT

Phone: 0145688899

Email: [email protected]

Patrick HOCHEDEZ, Dr

Role: CONTACT

Phone: 0140669604

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Patrick HOCHEDEZ, Dr

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2024-113

Identifier Type: -

Identifier Source: org_study_id